On December 5, 2022 Herantis Pharma Plc ("Herantis") reported that as notified earlier on December 1, 2022, it has applied for delisting of its shares from Nasdaq First North Growth Market Sweden ("Nasdaq FN GM Sweden") (Press release, Herantis Pharma, DEC 5, 2022, View Source;approved-delisting-application-regarding-the-secondary-listing-on-the-nasdaq-first-,c3677358 [SID1234624763]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nasdaq Stockholm AB approved the application December 2, 2022 and decided to delist the shares of Herantis (trading code HRNTS, ISIN code FI4000087861) from Nasdaq FN GM Sweden.
The last day of trading in the shares of Herantis on Nasdaq First North Growth Market Sweden shall be January 31, 2023.
The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy.
Aqurat Fondkommission AB acts as Herantis’ Issuing Agent and will coordinate the conversion process:
Instructive letter will be distributed to directly registered shareholders and to all custodians
The instructive letter explains the conversion process and actions to be taken
Cross-border settlement will be done weekly
Shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB ([email protected]) for more information.